United Therapeutics Expands Regenerative Medicine Portfolio With Thymmune Acquisition

United Therapeutics announced the acquisition of Thymmune Therapeutics, a pre-clinical biotech focused on regenerative thymic cell therapies, for $140 million in cash plus up to $160 million in milestone-based earn-outs through 2031. The deal expands UTHR’s regenerative medicine portfolio and complements its UThymoKidney organ-replacement program. Thymmune’s lead candidate, THY-100, is being studied for congenital athymia, a rare and life-threatening immune disorder in infants. The transaction reinforces United Therapeutics’ strategy to combine cell engineering with organ manufacturing and could broaden its long-term pipeline in immune restoration and transplant medicine. The stock context was modestly positive, with UTHR closing at $547.15, up 0.98% after trading between $272.12 and $609.35 over the past year.